BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18349031)

  • 21. Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review.
    Alwasaidi TA; Hamadah A; Altouri S; Tay J; McDiarmid S; Faught C; Allan D; Huebsch L; Bredeson C; Bence-Bruckler I
    Cancer Med; 2015 Dec; 4(12):1817-27. PubMed ID: 26432256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
    Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L; King N; Lechowicz MJ; Lonial S; Sinha R; Flowers CR
    Leuk Lymphoma; 2015 Feb; 56(2):383-9. PubMed ID: 24828864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?
    Geisler C; Kolstad A; Laurell A; Räty R; Nordic Lymphoma Group ; Mantle Cell Lymphoma Subcommittee
    Leuk Lymphoma; 2009 Aug; 50(8):1249-56. PubMed ID: 19562619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Chihara D; Cheah CY; Westin JR; Fayad LE; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak LW; Wang ML; Romaguera JE
    Br J Haematol; 2016 Jan; 172(1):80-8. PubMed ID: 26648336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy of mantle cell lymphoma].
    Udvardy M
    Orv Hetil; 2009 Dec; 150(50):2253-7. PubMed ID: 19951856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous stem cell transplantation in patients with mantle cell lymphoma.
    Oinonen R; Jantunen E; Itälä M; Lehtinen T; Kuittinen O; Franssila K; Wiklund T; Elonen E
    Leuk Lymphoma; 2002 Jun; 43(6):1229-37. PubMed ID: 12152990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of the Mantle Cell Lymphoma International Prognostic Index: A single-center retrospective analysis.
    Smith SD; Hsi E; Bolwell B; Pohlman B; Dean R; Effinger M; Maggiotto A; Sweetenham J
    Am J Hematol; 2010 Jun; 85(6):454-6. PubMed ID: 20513126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
    Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
    J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
    Lenz G; Dreyling M; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
    Romaguera JE; Fayad LE; Feng L; Hartig K; Weaver P; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak L; Wang M
    Br J Haematol; 2010 Jul; 150(2):200-8. PubMed ID: 20528872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blastoid mantle cell lymphoma presenting as acute leukemia: a case report.
    Dongre A; Kanchankar N; Deshmukh M; Wasnik D; Dongre T
    Pan Afr Med J; 2021; 39():150. PubMed ID: 34527166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
    Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
    Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
    Berinstein NL; Mangel J
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.
    Reddy N; Greer JP; Goodman S; Kassim A; Morgan DS; Chinratanalab W; Brandt S; Englehardt B; Oluwole O; Jagasia MH; Savani BN
    Exp Hematol; 2012 May; 40(5):359-66. PubMed ID: 22269117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
    Jo JC; Kim SJ; Lee HS; Eom HS; Lee SI; Park Y; Lee JO; Lee Y; Yhim HY; Yang DH; Byun JM; Kang HJ; Kim HJ; Shin HJ; Yoo KH; Suh C;
    Ann Hematol; 2020 Feb; 99(2):223-228. PubMed ID: 31853704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
    Kahl BS; Longo WL; Eickhoff JC; Zehnder J; Jones C; Blank J; McFarland T; Bottner W; Rezazedeh H; Werndli J; Bailey HH;
    Ann Oncol; 2006 Sep; 17(9):1418-23. PubMed ID: 16766582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mantle cell lymphoma: a Turkish Multi-Center Study.
    Okay M; Meletli O; Kelkitli E; Malkan UY; Turgut M; Buyukasik Y; Tekin F; Demiroglu H; Goker H
    J BUON; 2019; 24(5):2084-2089. PubMed ID: 31786879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.